ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
IPO Year:
Exchange: NASDAQ
Website: https://www.zimvie.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $16.00 | Buy | B. Riley Securities |
| 3/13/2025 | Buy → Hold | Needham | |
| 5/16/2024 | $20.00 | Hold → Buy | Needham |
| 11/16/2023 | Hold | Needham | |
| 12/21/2022 | $9.00 | Underweight | Barclays |
| 6/17/2022 | $20.00 | Neutral | JP Morgan |
| 3/18/2022 | Neutral | Guggenheim |
B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00
Needham downgraded ZimVie from Buy to Hold
Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00
Needham initiated coverage of ZimVie with a rating of Hold
Barclays initiated coverage of ZimVie with a rating of Underweight and set a new price target of $9.00
JP Morgan initiated coverage of ZimVie with a rating of Neutral and set a new price target of $20.00
Guggenheim initiated coverage of ZimVie with a rating of Neutral